OSIVAX
Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.
OSIVAX
Social Links:
Industry:
Biotechnology Clinical Trials Health Care
Founded:
2017-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.osivax.com
Total Employee:
11+
Status:
Active
Contact:
+33 4 37 65 55 03
Email Addresses:
[email protected]
Total Funding:
50.8 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Grant - Osivax
Anaxago
Anaxago investment in Series B - Osivax
Bpifrance
Bpifrance investment in Grant - Osivax
European Innovation Council
European Innovation Council investment in Series B - Osivax
European Innovation Council
European Innovation Council investment in Grant - Osivax
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series A - Osivax
Cédric Delorme
Cédric Delorme investment in Series A - Osivax
Anaxago
Anaxago investment in Series A - Osivax
Anaxago
Anaxago investment in Seed Round - Osivax
Official Site Inspections
http://www.osivax.com Semrush global rank: 5.93 M Semrush visits lastest month: 1.39 K
- Host name: cluster031.hosting.ovh.net
- IP address: 146.59.209.152
- Location: Norway
- Latitude: 59.9452
- Longitude: 10.7559
- Timezone: Europe/Oslo
More informations about "Osivax"
About Us - Osivax
Osivax is a clinical-stage biotechnology company developing a transformative pipeline of universal vaccines uniquely designed to leverage both arms of the immune system: superior T-cell …See details»
Osivax Awarded Grant from a Leading Non-Governmental …
Mar 28, 2023 Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has …See details»
Osivax - Crunchbase Company Profile & Funding
Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to …See details»
Osivax - LinkedIn
Osivax | 6,035 followers on LinkedIn. Pioneering A New Class of Universal Vaccines | Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle ...See details»
Osivax - Devex
Learn more about Osivax's jobs, projects, latest news, contact information and geographical presence. Osivax’ mission is to develop “universal” vaccines against highly-mutating viruses.See details»
Osivax - European Commission - European Innovation Council
Osivax is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. Osivax is focused on providing proof …See details»
Osivax - LinkedIn
Osivax | 5,803 followers on LinkedIn. Pioneering A New Class of Universal Vaccines | Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle …See details»
Osivax - Funding, Financials, Valuation & Investors - Crunchbase
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How …See details»
Osivax SAS - Drug pipelines, Patents, Clinical trials - Synapse
Osivax’s ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious …See details»
Osivax Awarded Grant from a Leading Non-Governmental …
For further information: www.osivax.com Contact Alexandre Le Vert, CEO [email protected] +33 (0) 9 70 30 13 80 For Media Inquiries Trophic Communications Valeria Fisher or …See details»
Osivax Company Profile 2025: Valuation, Funding & Investors
Osivax General Information Description. Developer of a universal vaccine designed to prevent globally impactful infectious diseases. The company's vaccine leverages its technology and …See details»
Osivax Announces Clinical and Preclinical Vaccine Data …
Sep 1, 2022 About Osivax Osivax is a biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM ®, to transform current and new …See details»
Osivax Company Profile - Office Locations, Competitors, Revenue …
Osivax is a clinical-stage biotechnology company developing a pipeline of vaccines and immunotherapies. Its flagship vaccine, OVX836, comprises a protein engineered to include the …See details»
Osivax Company Profile: Overview and Full News Analysis
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, announced today that the first participant has been …See details»
Osivax - EU-Startups
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology oligoDOM® inducing powerful CD8 T …See details»
News - Osivax
A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. Zhao X et al. npj Vaccines, 2024 Jun. 9:119. doi: 10.1038/s41541-024 …See details»
MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM …
1 day ago SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility; UI Pharmaceuticals is looking forward to supporting the need for larger clinical and commercial …See details»
Osivax - Products, Competitors, Financials, Employees, …
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836. Nov 14, 2024. LYON, France--(BUSINESS WIRE)--Osivax, a …See details»
Osivax Announces Promising Phase 2a Results with Universal …
Dec 21, 2021 Osivax, a biopharmaceutical company focused on preventing the spread of constantly mutating global infectious diseases, including influenza and coronaviruses, …See details»
Pipeline - Osivax
Osivax is creating a pipeline of universal vaccines to revolutionize infectious disease prevention and meet a significant medical need. These vaccine candidates are based on the oligoDOM …See details»